Dissemin is shutting down on January 1st, 2025

Published in

National Academy of Sciences, Proceedings of the National Academy of Sciences, 6(119), 2022

DOI: 10.1073/pnas.2113874119

Links

Tools

Export citation

Search in Google Scholar

Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells

Journal article published in 2022 by Razie Amraei, Chaoshuang Xia ORCID, Judith Olejnik ORCID, Mitchell R. White ORCID, Marc A. Napoleon, Saran Lotfollahzadeh ORCID, Blake M. Hauser, Aaron G. Schmidt ORCID, Vipul Chitalia, Elke Mühlberger ORCID, Catherine E. Costello ORCID, Nader Rahimi ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Significance Human angiotensin-converting enzyme 2 (ACE2) is the most widely known entry receptor for SARS-CoV-2. The possible involvement of other cellular components in viral entry mechanisms remains unknown. Vimentin is expressed in human endothelial cells, binds to SARS-CoV-2-spike, and expedites SARS-CoV-2 entry. Treatment of lung ACE2/A549 carcinoma cells with purified vimentin or coculture of ACE2/A549 cells with HEK-293 cells expressing vimentin increased ACE2-dependent viral entry. CR3022 antibody blocked vimentin interaction with SARS-CoV-2-spike and inhibited SARS-CoV-2 entry. Vimentin could facilitate SARS-CoV-2 infection and contribute to vascular complications associated with COVID-19.